GLP-1 receptor agonists, offering clinically proven and durable weight-loss outcomes, are thus positioned to capture expanding demand in obesity management, driving market growth globally and complementing their use in diabetes care
Considering the potential appetite-reducing effects of GLP-1 RAs, diet-restricted control groups were included for both drugs, ensuring consistent food intake between treatment and control groups, thereby minimizing any dietary bias
The areas that show change first depend on your body fat distribution pattern
It explored the mechanisms of action of GLP-1RAs and their therapeutic potential in a wide array of diseases, such as diabetes mellitus, providing new insights into metabolic disease management
Stomach pain or Paralysis In rare cases, semaglutide may cause gastroparesis, in which the stomach empties food more slowly than usual